WO2000002924A1

WO2000002924A1 - Papillomavirus cellular receptor

Info

Publication number: WO2000002924A1
Application number: PCT/US1999/015249
Authority: WO
Inventors: W. Martin Kast; John D. Nieland
Original assignee: Loyola University Chicago
Current assignee: Loyola University Chicago
Priority date: 1998-07-13
Filing date: 1999-07-07
Publication date: 2000-01-20
Anticipated expiration: 2001-01-13
Also published as: EP1104442A1; US6242176B1; US20010028883A1; AU4971099A; CA2337101A1

Abstract

The present invention provides methods and reagents for treating or preventing papillomavirus infection. In one aspect, the invention provides reagents and methods for attenuating the ability of papillomavirus to bind to cells by blocking access of papillomavirus to its cellular receptor. In another aspect, the invention provides reagents and methods for attenuating the ability of papillomavirus to infect cells by reducing the free titer of papillomavirus. In yet another aspect, the invention provides a complex comprising a biologically active substance and a ligand that recognizes CD16 and a method of delivering a biologically active substance to a papillomavirus-infected cell using the complex.

Description

PAPILLOMA VIRUS CELLULAR RECEPTOR

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT This invention was made with Government support under Grant Number

RO1 CA74397 awarded by the National Institutes of Health. The United States Government may have certain rights in this invention.

TECHNICAL FIELD OF THE INVENTION The present invention relates to methods and reagents for treating or preventing papiUomavirus infection.

BACKGROUND OF THE INVENTION

PapiUomavirus are causative agents for several types of epithelial and mucosal diseases. Of particular concern is that certain strains of papiUomavirus are associated with cervical and penile cancers (see, e.g., Iwasawa et al., J. Urol, 149, 59-63 (1993); Koutsky et al., N. Engl. J. Med., 327, 1272-78 (1992)). Considerable efforts, therefore, are underway to prevent the spread of this virus by developing a prophylactic vaccine and novel treatments for papillomavirus- induced lesions (see, e.g., Cason et al., Vaccine, 11, 603-1 1 (1993); Crawford,

Cancer Surv., 16, 215-29 (1993)). Such efforts, however, have been hampered by the particular difficulties of working with papiUomavirus in vitro. To complete its life cycle, papiUomavirus requires its host cell to undergo a differentiation event. Currently, no in vitro culture system duplicates this state adequately to permit efficient papiUomavirus growth in vitro.

Papillomaviruses are nonenveloped double-stranded DΝA viruses about 55 nm in diameter with an approximately 8-kb genome in a nucleohistone core (Baker et al, Biophys J. 60, 1445-56 (1991)). The capsids include two viral proteins (LI and L2) of about 55 kDa and 75 kDa, respectively (Larson et al., J. Virol, 61, 3596-3601 (1987)). LI is the major capsid protein, and it is arranged in 72 pentameres within the capsid. In fact, LI has the ability to self- assemble into virus-like particles (VLPs) upon production of the LI protein in eukaryotic cells (see, e.g., Hagensee et al., J. Virol., 67, 315-22 (1993); Kirnbauer et al., J. Virol, 67, 6929-36 (1993)). The function and position of L2 within the virion are not clear, although the protein is assembled with L 1 into VLPs when coexpressed in cells. Because of the lack of suitable papiUomavirus culture conditions, VLPs typically are used for in vitro studies of papiUomavirus infection, as opposed to intact papiUomavirus (see, e.g., Roden et al., J. Virol, 68, 7260-66 (1994); Volpers et al., J. Virol, 69, 3258-64 (1995)). Using VLPs, it is now thought that a putative cell receptor for papiUomavirus is expressed across a wide range of cell types and is highly conserved between a diverse group of organisms (see, e.g., Mϋller et al., J. Virol, 69, 948-54 (1995); Volpers et al., supra; Roden et al, supra). Currently, little is understood about papiUomavirus infection, particularly the identity of a cell surface receptor recognizing papiUomavirus. In view of the foregoing problems, there exists a need for methods and reagents for treating or preventing papiUomavirus infection.

BRIEF SUMMARY OF THE INVENTION

The present invention is predicated, at least in part, on the discovery that papiUomavirus selectively binds the CD 16 protein present in a variety of cells. Using this discovery, the present invention provides methods and reagents for treating or preventing papiUomavirus infection. In one aspect, the present invention provides reagents and methods for attenuating the ability of papiUomavirus to bind to cells by blocking access of papiUomavirus to its cellular receptor. In another aspect, the present invention provides a method of attenuating the ability of papiUomavirus to infect cells by reducing the free titer of papiUomavirus. In another aspect, the present invention provides a complex comprising a biologically active substance and a ligand that recognizes CD 16 and a method of delivering a biologically active substance to an HVP-infected cell using the complex. These and other advantages of our invention, as well as additional inventive features, will be apparent from the following detailed description.

DETAILED DESCRIPTION OF THE INVENTION The present invention provides methods and reagents for treating or preventing papiUomavirus infection. In one aspect, the method attenuates the ability of papiUomavirus to bind cells. One method of attenuating the ability of papiUomavirus to bind cells is to expose the cells to a ligand that recognizes CD 16 under conditions sufficient for the ligand to bind CD 16. The bound ligand interferes with subsequent interaction between papiUomavirus and the CD 16 molecules; thus, by such treatment, the ability of papiUomavirus to subsequently bind cells is attenuated. In this context, the ligand is present on any molecule suitable for blocking the interaction between papiUomavirus and the bound CD 16 protein. While many types of molecules can provide the ligand, generally the ligand is present as part of a protein. For example, the ligand can be an antibody recognizing an epitope on CD 16. In other embodiments, the ligand is on a protein including an external domain of an papiUomavirus capsid protein (e.g., LI, L2, or a soluble derivative of LI or L2 retaining an extracellular domain). The residues that comprise the ligand in a protein need not necessarily be contiguous in the chain of amino acids that make up the protein. In other words, the ligand can be generated by the particular conformation of the protein, e.g., through folding of the protein in such a way as to bring contiguous and/or noncontiguous sequences into mutual proximity. Such proteinatious species can be synthesized using standard direct peptide synthesizing techniques (see, e.g., Bodanszky, Principles of Peptide Synthesis (Springer- Verlag, Heidelberg: 1984)), such as via solid-phase synthesis (see, e.g., Merrifield, J. Am. Chem. Soc, 85, 2149-54 (1963); Barany et al., Int. J. Peptide Protein Res., 30,

705-739 (1987); and U.S. Patent 5,424,398). Alternatively, such modified proteins can be chemically crosslinked, and a variety of cross-linking agents are known in the art and widely available (e.g., succinimidyl or maleimidyl cross-linkers). Methods for conjugating peptides and polyamines are also well-known in the art (see, e.g., Staros, Biochem., 21, 3990 (1982)). Alternatively, a DNA fragment encoding the protein can be subcloned into an appropriate vector using well known molecular genetic techniques. The fragment is then transcribed and the peptide subsequently translated in vitro within a host cell. Any appropriate expression vector (see, e.g., Pouwels et al., Cloning Vectors: A Laboratory Manual (Elsevior, NY: 1985)) and corresponding suitable host cells can be employed for production of recombinant peptides. Expression hosts include, but are not limited to, bacterial species, mammalian or insect host cell systems including baculovirus systems (e.g., as described by Luckow et al., Bio/Technology, 6, 47 (1988)), and established cell lines such 293, COS-7, C127, 3T3, CHO, HeLa. BHK, etc. From such cells, the modified chimeric proteins can be harvested by standard techniques. The ligand is exposed to the cells, e.g., under conditions suitable for the ligand to bind the CD 16 protein. For example, for cells in vitro, the ligand-bearing molecules can be added to the cell culture for a time sufficient for them to bind the CD 16 molecules on the cells. For cells in vivo, the ligand-bearing molecules can be supplied in a pharmacologically acceptable carrier (e.g., a solution, gel, magma, or salve). In this regard, the ligand can be delivered topically to cells within a discrete organ or tissue or systemically to attenuate papiUomavirus infection on a more wide-spread scale.

The ligand recognizing CD 16 is exposed to the cells under conditions sufficient for the ligand to bind the cells. The concentration of ligand, as well as the conditions required for efficient binding, will depend on the type of ligand employed and location of delivery. However, it is within the routine skill in the art to investigate the kinetic profile of such ligands in advance of an application.

In accordance with the present invention, another method of attenuating the ability of papiUomavirus to infect cells is to reduce the free titer of papiUomavirus. In the context of the invention, this can be achieved by exposing papiUomavirus to a ligand that recognizes the surface of an papiUomavirus under conditions sufficient for the ligand to bind the papiUomavirus. The resultant papillomavirus/ligand complex is less able to infect cells than unbound papiUomavirus (i.e., it forms a noninfective complex). In this context, the ligand can be present on any molecule suitable for interacting with papiUomavirus. While many types of molecules can provide the ligand, generally the ligand is present as part of a protein. For example, the ligand can be an antibody recognizing the surface of the papiUomavirus virion (or one of the two capsid proteins). Many such antibodies are known in the art, and some are commercially available. In other embodiments, the ligand is present in a protein including an external domain from the CD 16 protein. For example, soluble derivatives of the CD 16 protein are disclosed in published international application WO 89/11490. Where the ligand is proteinatious, the protein can be manufactured by any suitable method, such as the methods discussed above. The ligand recognizing papiUomavirus is exposed to the virus under conditions suitable for the ligand to bind papiUomavirus. For example, to attenuate infection of cells in vitro, the ligand can be added to the culture solution. To attenuate in vivo infection, the papillomavirus-ligand can be supplied in a pharmacologically acceptable carrier (e.g., a solution, gel, magma, or salve). In this regard, for example, a pharmacologically-acceptable carrier containing the ligand recognizing papiUomavirus can be injected into a patient (e.g., intravenously, subcutaneously, etc.) or applied to the skin or mucosa to reduce the titer of papiUomavirus. Alternatively, the ligand recognizing papiUomavirus can attenuate infection of cells within a discrete organ or tissue (e.g., a tumor) by supplying the carrier containing the ligand to the tissue.

This strategy can also be employed to reduce the transmission of papiUomavirus. For example, as papiUomavirus is a sexually-transmitted virus, the ligand recognizing papiUomavirus can be applied vaginally. for example in a creme, douche, sponge or other suitable carrier. Alternatively, a carrier containing the ligand can be used to coat a condom or similar device to attenuate viral transmission between individuals. To reduce viral titer, the ligand recognizing the papiUomavirus surface is exposed to the papiUomavirus under conditions sufficient for the ligand to bind the papiUomavirus. The concentration of ligand, as well as the conditions required for efficient binding, will depend on the type of ligand employed and location of delivery. However, it is within the routine skill in the art to investigate the kinetic profile of such ligands in advance of an application.

Regardless of the type of ligand employed (e.g., either a ligand recognizing papiUomavirus or a ligand recognizing CD 16), the present inventive method attenuates the ability of the virus to infect cells. In many cases, the ability of papiUomavirus to bind a population of cells is reduced by at least an order of magnitude. Typically, the method can substantially reduce, or even practically eliminate, the ability of the virus to bind to, and therefore infect, cells. However, even in protocols in which some residual viral infection still occurs, the method is a useful prophylaxis or therapy for papillomavirus-associated disorders. Indeed, any reduction in the incidence of viral infection renders it less likely that a given papiUomavirus infection will spread or be transmitted between individuals.

Moreover, protocols, such as the inventive method, that attenuate viral infection can be used in combination with other regimens to combat papiUomavirus infective diseases.

Aside from attenuating the ability of papiUomavirus to infect cells, the discovery that papiUomavirus binds CD16 affords a method of delivering a pharmacologically active substance to a papillomavirus-infected cell. This method uses a complex including a pharmacologically active substance and a ligand recognizing CD 16. The complex is exposed to the papillomavirus-infected cells under conditions sufficient for the ligand to bind CD 16 on the cells. The pharmacologically active substance is thus brought into proximity to, and delivered to, the infected cell. The use of this method permits the targeted delivery of the pharmacologically active substance to the infected cells. This permits the employment of relatively high concentrations of many pharmacologically active agents to be delivered to the infected cells without many of the concomitant side effects attributed to the activity of such agents in noninfected cells.

For use in this method, the complex includes at least a ligand recognizing CD 16 and a pharmacologically active substance. In this regard, the ligand is present on any molecule suitable for interacting with the CD 16 protein present on papillomavirus-infected cells, such as the molecules described above. The complex is delivered to the infected cells similarly to the manner described above. Within the complex, the pharmacologically active substance can be any compound that exerts a biological effect on the infected cells. For example, for treating tumors (e.g., cervical or penile cancers), warts, or other papillomavirus- related lesions, the pharmacologically active substance can be a medicament, cytotoxin, chemotherapeutic agent, radioactive agent, etc.

In other embodiments, the pharmacologically active substance is a gene encoding a bioactive molecule. In such circumstances, the complex delivers the gene to the infected cells such that the cells internalize the gene and express it to produce the bioactive molecule. For combating tumors associated with papiUomavirus infection, the gene can encode a cytokine (e.g., tumor necrosis factor (TNF), TGF-α, TGF-β, interleukins (IL) such as IL-1, IL-2, IL-3, etc., GM- CSF, G-CSF, M-CSF, co-stimulatory factor B7, etc.), a protein that promotes cell death or an enzyme that converts a prodrug into a cytotoxin (e.g., HSV-tk, cytosine deaminase, xanthine/guanine phosphoribosyltransferase, cytochrome p450 2B1, etc.). Still other bioactive molecules are RNA species having sequences antisense to portions of papiUomavirus genes (e.g., the genes encoding L1, L2).

The complex can be formed in any suitable manner. In one embodiment, the complex can be proteinatious (e.g., a chimeric protein having the papiUomavirus ligand as a first domain and the pharmacologically active substance as a second domain). For example, the complex can comprise all or a portion of the CD 16 molecule fused to a toxin. A preferred chimeric complex includes a soluble portion of the CD 16 molecule fused to a portion of the Pseudomonas endotoxin A (see, e.g., U.S. Patent 5,587,455). Such proteinatious agents can be manufactured by any appropriate method, such as those discussed above. Many such complexes include non-proteinatious components. For example, such a complex can incorporate nucleic acids (e.g., encoding the genes described above). In other embodiments, the complex can include an agent for tethering the pharmacologically active substance to the ligand. For example incorporating lipids into the complex (e.g., in the form of liposomes) enhances cellular uptake of many types of pharmacologically active agents, especially nucleic acids. The use of such lipids is especially preferred when the ligand component of the complex is of viral origin (e.g., LI, L2, a VLP, etc.) (see, e.g., Innes et al, J. Virol, 64, 957-61 (1990); Morishaita et al., Hypertension, 21, 894- 99 (1993); U.S. Patent 5,635,380). Where a liposome is employed in the complex, and where a nucleic acid is the pharmacologically active agent, preferably the liposome contains cationic lipids, but can contain neutral lipids as well. Preferred cationic lipids include LIPOFECTIN (DOTMA) (Gibco BRL), LIPOFECTMINE (Gibco BRL), and DOTAP (Boeringer-Mannheim), and others are known in the art (see, e.g., U.S. Patent 5,736,392).

Such complexes including non-proteinatious components can be created by mixing the ligand with the lipid and/or nucleic acid and allowing the complexes to form. The mixing can occur, for example, in a serum-free culture medium, and can occur under any suitable temperature.

While it is believed that one of skill in the art is fully able to practice the present invention after reading the foregoing detailed description, the following examples are set forth to further illustrate some of its features. In particular, these examples demonstrate that papiUomavirus can selectively bind the CD 16 cell- surface molecule, that a ligand recognizing the CD 16 cell surface molecule can block papiUomavirus attachment to cells, that various papillomavirus-induced tumors express the CD 16 molecule, that CD 16 expression is associated with HPV binding in vivo, and that HPV binds cells poorly unless they express CD16. The procedures employed in these examples, such as affinity chromatography, Southern blots, PCR, DNA sequencing, vector construction (including DNA extraction, isolation, restriction digestion, ligation, etc.), cell culture (including antibiotic selection), transfection of cells, protein assays (Western blotting, immunoprecipitation, immunofluorescence), in situ hybridization, etc., are techniques routinely performed by those of skill in the art (see generally Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989)). Accordingly, in the interest of brevity, the basic experimental protocols are not discussed in detail. As these examples are included for purely illustrative purposes, they should not be construed to limit the scope of the invention in any respect.

EXAMPLE 1 This example demonstrates that CD 16 is a cellular receptor for papiUomavirus.

The ability of a ligand recognizing the CD 16 protein to block papiUomavirus binding was assayed by FACS analysis using cocktails of antibodies recognizing various cell surface proteins. Single cell suspensions of human peripheral blood lymphocytes obtained with the consent of a donor were created.

PapiUomavirus binding was assessed using papiUomavirus L1/L2 VLPs (Greenstone et al., Proc. Nat. Acad. Sci. USA, 95, 1800-05 (1998)). To assess signal, these VLPs were biotinylated by incubating them with N-hydroxy- succinimide-biotin for one hour at room temperature. The VLPs were dialyzed against standard phosphate-buffered saline for four hours and then stored at -80 °C for later use. Biotinylation was assessed using a sandwich ELISA. At a 100-fold dilution, biotinylated VLPs registered positive, while control VLPs exhibited little absorption signal.

The cell populations were incubated on ice with the biotinylated VLPs for two hours. Following the incubation, populations of cells were incubated with streptavidin-APC and the various antibody cocktails indicated in Table 1. Following this second incubation, the cells were exposed to labeled secondary antibody (rat or mouse FITC-conjugated Ig). In blocking experiments, the cells were pre-incubated with antibodies for one hour on ice. The antibodies employed recognized, respectively, CD16, CD21, CD23, CD32, CD64, α6 integrin, and β4 integrin. Fluorescence was assessed and quantified using a FACS-Calibur with CELLQUEST software (Becton-Dickinson). The number of cells gated for MCH class II and bound to biotinylated VLP were counted.

The data revealed that only when the anti-CD 16 antibody was absent from the cocktail did the papiUomavirus VLPs bind to the cells with wild-type efficiency. Significantly, these results demonstrate that exposing cells to a ligand recognizing CD16 (e.g., the anti-CD16 antibody used in these experiments) attenuates papiUomavirus binding. Importantly, the results indicate that interfering with the interaction between the VLPs and the 6 integrin with the α6 antibody had no effect on viral binding. This result is surprising because it is inconsistent with a prior suggestion that the α6 integrin may be a papiUomavirus receptor (Evander et al., J. Virol, 77(3), 2449-56 (1997)).

EXAMPLE 2

This example demonstrates that cells associated with papiUomavirus infection express CD 16 on the cell surface. Various cell lines (i.e., RD cells (a monkey kidney cell line), HeLa cells (a human papiUomavirus strain 18-expressing cervical cancer cell line). CV1 cells (a monkey kidney cell line), BB49 cells (a human papiUomavirus strain 6-expressing head and neck cancer cell line), Caski cells (a human papiUomavirus strain 16- expressing cervical cancer cell line), and Epstein-Barr Virus-transformed cells)) were assayed for CD 16 expression using an antibody recognizing CD 16. The total number of cells in each population, and the number of such cells expressing CD16, were measured by FACS analysis as described above.

The results revealed that the number of cells expressing CD 16 approximated the number of cells in each population, indicating that papillomavirus-infected cells express CD 16. These results are consistent with published immunohistochemical data demonstrating that CD 16 is expressed in tissue associated with HPV lesions, but not expressed in other tissues (compare Hussain et al., AIDS, 5, 1089-94 (1991), Hussain et al., Clin Exp. Immunol, 90, 530-38 (1992), and Hussain et al., Immunology, 85, 475-84 (1995)).

EXAMPLE 3 This example demonstrates that CD16 expression correlates with HPV binding in situ.

Frozen sections of human foreskin epithelium were incubated with either biotinylated HPV 16 L1/L2 VLPs, an anti-human CD 16 monoclonal antibody, an anti-human α6 integrin, or an anti-human β4 integrin. The sections exposed to VLPs were then incubated with peroxidase-labeled streptavidin, and the sections exposed to the antibodies were incubated with peroxidase-labeled secondary antibodies. Subsequently, each section was developed with peroxidase substrate.

Histological examination of each section revealed α6 and β4 integrin staining in a well-defined deep stratum of dermis, stratum basale, well away from the surface of the foreskin. Conversely, CD 16 staining was observed in a discrete layer of tissue at the surface of the foreskin. HPV particles were detected only in the region in which CD 16 was detected, and not in the regions in which α6 and β4 integrin were detected. This result is surprising because it is inconsistent with a prior suggestion that α6 or β4 integrins may be papiUomavirus receptors (Evander et al., supra).

EXAMPLE 4 This example demonstrates that HPV binding in vivo is reduced in the absence of CD16.

Biotinylated HPV 16 L1/L2 VLPs were incubated with splenocytes from either C57 Bl/6 or CD 16 knockout mice. Non-biotinylated HPV 16 L1/L2 VLPs were used as a control. After incubation, the cells were washed, and VLP binding was assayed using allophycocyanin-labeled streptavidin. Fluorescence was assessed using a Becton Dickinson FacsCalibur running CellQuest software.

The data revealed that the VLPs bound the knockout cells with only about half the efficiency to which they bound wild-type cells expressing CD 16. These results demonstrate that CD 16 is required for high-efficiency papiUomavirus infection.

All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference. While the present invention has been described with an emphasis upon preferred embodiments and illustrative examples, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and that the present invention can be practiced otherwise than as specifically described herein. Accordingly, the present invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

Claims

WHAT IS CLAIMED IS:

1. A method of attenuating the ability of papiUomavirus to bind cells, said method comprising exposing cells to a ligand that recognizes CD 16 under conditions sufficient for said ligand to bind said CD 16, whereby the ability of said papiUomavirus to subsequently bind said cells is attenuated.

2. The method of claim 1, wherein said ligand is an antibody recognizing an epitope on said CD 16.

3. The method of claim 1, wherein said ligand is a protein comprising an external domain of a papiUomavirus capsid protein.

4. A method of attenuating the ability of papiUomavirus to infect cells, said method comprising exposing papiUomavirus to a ligand that recognizes the surface of a papiUomavirus under conditions sufficient for said agent to bind said papiUomavirus to form a noninfective complex.

5. The method of claim 4, wherein said ligand is a soluble CD 16 peptide.

6. A method of delivering a pharmacologically active substance to an HVP- infected cell, said method comprising exposing an HVP-infected cell to a complex comprising a pharmacologically active substance and a ligand that recognizes CD 16 under conditions sufficient for said ligand to bind CD 16 on said cell such that said pharmacologically active substance is delivered to said cell.

7. The method of claim 6, wherein said complex comprises an agent for tethering said pharmacologically active substance to said ligand.

8. The method of claim 6 or 7, wherein said complex comprises a liposome.

9. The method of any of claims 6-8, wherein said ligand is an antibody recognizing an epitope on said CD 16.

10. The method of any of claims 6-9, wherein said ligand is a protein comprising an external domain of an papiUomavirus capsid protein.

11. The method of any of claims 6-10, wherein said pharmacologically active substance comprises a cytotoxic protein, a chemotherapeutic agent, or a radioactive agent.

12. The method of any of claims 6-10, wherein said pharmacologically active substance comprises a gene encoding a bioactive molecule, and said gene is expressed in said cell to produce said bioactive molecule.

13. The method of claim 12, wherein said bioactive molecule is a protein that promotes cell death.

14. The method of claim 13, wherein said protein is an enzyme that converts a prodrug into a cytotoxin.

15. The method of claim 12, wherein said bioactive molecule is an RNA having a sequence antisense to a portion of an papiUomavirus gene.

16. The method of any of claims 6-15, wherein said complex comprises a chimeric protein having a first domain comprising said ligand and a second domain comprising said pharmacologically active substance.

17. A complex comprising a pharmacologically active substance and a ligand that recognizes CD 16.

18. The complex of claim 17, further comprising an agent for tethering said pharmacologically active substance to said ligand.

19. The complex of claim 17 or 18, further comprising a liposome.

20. The complex of any of claims 17-19, wherein said ligand is an antibody recognizing an epitope on said CD16.

21. The complex of any of claims 17-20, wherein said ligand is a protein comprising an external domain of an papiUomavirus capsid protein.

22. The complex of any of claims 17-21 , wherein said pharmacologically active substance comprises a cytotoxic protein, a chemotherapeutic agent, or a radioactive agent.

23. The complex of any of claims 17-22, wherein said pharmacologically active substance comprises a gene encoding a bioactive molecule.

24. The complex of claim 23, wherein said bioactive molecule is a protein that promotes cell death.

25. The complex of claim 24, wherein said protein is an enzyme that converts a prodrug into a cytotoxin.

26. The complex of claim 23, wherein said bioactive molecule is an RNA having a sequence antisense to a portion of a papiUomavirus gene.

27. The complex of any of claims 17-26, comprising a chimeric protein having a first domain comprising said ligand and a second domain comprising said pharmacologically active substance.